RE: Affimers are the way forward30 Sep 2020 13:34
Larsh - You missed a bit
Avacta was able to identify and characterize highly specific, reproducible SARS-CoV-2 Affimer binders within just four weeks and is currently working with multiple partners to develop laboratory, point-of-care, and self-tests to increase global testing capacity. Aptamer Group is likewise instigating various partnership opportunities as well as seeing the utility of its products to detect SARS-CoV-2 in wastewater. As awareness grows around how antibody alternatives can diversify and strengthen the portfolio of reagents available to researchers, it is widely agreed that their use will increase significantly in the near future.